Nuray AKTAY-AYAZ, Gonca KESKİNDEMİRCİ, Aysel KIYAK, Nevin HATİPOĞLU, Mustafa ÇAKAN, Çiğdem AYDOĞMUŞ, Gönü AYDOĞAN, Hilal AKI

Coexistence of early onset sarcoidosis and partial interferon-? receptor 1 deficiency

Çakan M, Keskindemirci G, Aydoğmuş Ç, Akı H, Hatipoğlu N, Kıyak A, Aydoğan G, Aktay-Ayaz N. Coexistence of early onset sarcoidosis and partial interferon-? receptor 1 deficiency. Turk J Pediatr 2016; 58: 545-549.Pediatric sarcoidosis comprises a spectrum of childhood granulomatous inflammatory conditions. Pathological hallmark of the disease is granuloma formation that is seen in the affected tissues and almost any organ or system can be involved. There are two forms of pediatric sarcoidosis. One is seen in older children and the clinical picture is very similar to that of adult sarcoidosis and the other one is seen in early childhood. Sarcoidosis in early childhood can be divided as Blau syndrome (familial form) and early onset sarcoidosis (sporadic form). In both of the diseases there is a defect in the NOD2/CARD15 gene. The typical triad of early onset sarcoidosis is polyarthritis, dermatitis and uveitis. Interferon-? receptor 1 deficiency is caused by defects in the IFN?R1 gene and non-tuberculosis mycobacterial pathogens are the leading causes of infections that start in early childhood. Herein we report a patient who presented with the symptoms of early onset sarcoidosis and also had partial interferon-? receptor 1 deficiency that presented with BCG-osis. In addition to anti-mycobacterial treatment, methotrexate and prednisolone were used in therapy.

PDF

___

1. Rosé CD, Wouters CH. Pediatric sarcoidosis. In: Cassidy JT, Petty RE, Laxer ML, Lindsey CB (eds). Textbook of Pediatric Rheumatology (6th ed). Philadelphia: Elsevier, 2011: 544-551.
2. Okafuji I, Nishikomori R, Kanazawa N, et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 2009; 60: 242-250.
3. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29: 19-20.
4. Aróstegui JI, Arnal C, Merino R, et al. NOD2 geneassociated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007; 56: 3805- 3813.
5. Rosé CD, Aróstegui JI, Martin TM, et al. NOD2- associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort. Arthritis Rheum 2009; 60: 1797-1803.
6. Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008; 122: 1043-1051.
7. Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004; 364: 2113-2121.
8. Edeer Karaca N, Boisson-Dupuis S, Aksu G, et al. Granulomatous skin lesions, severe scrotal and lower limb edema due to mycobacterial infections in a child with complete IFN-? receptor-1 deficiency. Immunotherapy 2012; 4: 1121-1127.
9. Caso F, Rigante D, Vitale A, et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol 2013; 2013: 513782.
10. Kanazawa N, Okafuji I, Kambe N, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-?B activation: common genetic etiology with Blau syndrome. Blood 2005; 105: 1195-1197.
11. Fink CW, Cimaz R. Early onset sarcoidosis: not a benign disease. J Rheumatol 1997; 24: 174-177.
12. Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open 2015; 1: e000097.
13. Saboor SA, Johnson NM, McFadden J. Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet 1992; 339: 1012-1015.
14. Mangiapan G, Hance AJ. Mycobacteria and sarcoidosis: an overview and summary of recent molecular biological data. Sarcoidosis 1995; 12: 20-37.
15. Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-? immunity. Semin Immunol 2014; 26: 454-470.
16. Osborne GE, Mallon E, Mayou SC. Juvenile sarcoidosis after BCG vaccination. J Am Acad Dermatol 2003; 48: 99-102.
17. Sakai H, Ito S, Nishikomori R, et al. A case of earlyonset sarcoidosis with a six-base deletion in the NOD2 gene. Rheumatology 2010; 49: 194-196.